Rectal cancer survival rates by stage
If you have been diagnosed with rectal cancer and you are looking for numbers, here they are. Five-year relative survival, from US SEER data published by the American Cancer Society for patients diagnosed between 2014 and 2020:
| How far the cancer has spread | 5-year survival |
|---|---|
| Localised (confined to the rectal wall) | 90% |
| Regional (reached nearby lymph nodes) | 74% |
| Distant (metastases in other organs) | 18% |
| All cases combined | 67% |
Before drawing any conclusion from that table, read the rest of this article. These figures are real, but they are also systematically more pessimistic than what happens today, and none of them describes a specific person.
What “5-year relative survival” means
It is the most misunderstood phrase in oncology.
It does not mean you live five years and then it ends. It means the percentage of patients alive five years after diagnosis, compared with people of the same age and sex without cancer. Most of those who reach five years live far longer — in rectal cancer, if the disease has not returned within the first five years, the risk of recurrence becomes very small.
The five-year mark is a statistical convention, chosen because it is long enough to be meaningful and short enough to allow results to be published. It is not a deadline.
Why the numbers are worse than reality
This is the part you will not find on most websites, and it is the most important.
A five-year survival figure published today describes people diagnosed at least five years ago, and treated with what was known then. The figures in the table come from patients diagnosed between 2014 and 2020. The American Cancer Society itself warns about this: people diagnosed now may have a better outlook than the numbers show, because treatments have improved in the meantime.
In rectal cancer, what has changed in recent years is not marginal:
- Total mesorectal excision done properly has reduced local recurrence from 10-30% to 4-10%; in the 1970s and 1980s it ran between 15% and 40%
- Pelvic MRI now allows patients to be selected before surgery, so that treatment fits the tumour rather than everyone receiving the same
- The watch and wait strategy allows some patients with a complete response to avoid surgery altogether
- Chemotherapy and targeted therapy have improved survival in metastatic disease
In other words: the 74% figure for node-positive disease describes patients operated on before many of these improvements became widespread.
Careful: “localised” does not mean “stage I”
This is where many people get lost, and why you cannot find the figure you are looking for.
SEER statistics use three categories — localised, regional, distant — which are not the same as stages I, II, III and IV that appear in your pathology report. The approximate correspondence is:
- Localised ≈ stage I and part of stage II. The tumour has not gone beyond the rectal wall and has not reached lymph nodes.
- Regional ≈ stage III, plus the part of stage II where the tumour has breached the wall but nodes are clear
- Distant = stage IV. There are metastases in the liver, lungs or other organs.
If you want to understand exactly what the stage in your report means, I have explained it at length in the article on rectal cancer stages.
Stage IV is not one single situation
The 18% figure for metastatic disease is the most frightening, and also the most misleading, because it lumps together completely different situations.
A patient with resectable liver metastases — few, in a part of the liver that can be removed — does not have the same prognosis as a patient with disease spread across several organs. After resection of colorectal liver metastases, five-year survival is 40-50%, and in patients who respond well to chemotherapy beforehand it reaches 64%.
That means selected stage IV disease is operated on with curative intent, not merely for relief. I have covered these situations in the article on stage IV rectal cancer.
Why the statistic does not describe you
An average calculated across tens of thousands of people says nothing about what happens to one. The factors that shift your position relative to the average are numerous:
- Age and general condition — a 45-year-old with no other illness tolerates full treatment quite differently from an 80-year-old with heart failure
- Where the tumour sits in the rectum and how close it is to the sphincter
- The circumferential resection margin on MRI, which predicts the risk of local recurrence
- Response to neoadjuvant treatment — a complete response changes the prognosis radically
- The quality of the operation. In rectal cancer, the quality of the mesorectal excision is itself a prognostic factor, and centre volume matters
- Molecular profile — MSI, RAS and BRAF mutations
All published figures also include patients who presented late, who did not complete treatment, or who were operated on in centres without experience in rectal surgery.
What you can influence
This is the useful part, because the list is not empty:
Where you have surgery. Rectal surgery is operator-dependent to a greater degree than almost any other digestive cancer surgery. An incompletely excised mesorectum raises the risk of local recurrence regardless of the rest of the treatment.
Complete the staging before any decision. Pelvic MRI, thoraco-abdominal CT and full colonoscopy. An operation performed without MRI in rectal cancer is an operation performed blind.
Finish the treatment. Adjuvant chemotherapy stopped halfway does not deliver the benefit seen in trials.
Attend follow-up. 85% of recurrences appear within the first three years, and a recurrence found early may still be operable with curative intent. A recurrence found late usually is not.
Do not delay. Between a localised cancer with 90% five-year survival and a metastatic one with 18% often lies precisely the interval during which symptoms were blamed on something else.
How to read a prognosis figure
If anyone gives you a number — including this article — you deserve to know three things about it: which patients it came from, from which years, and whether it covers your stage or a broader category. Without those, the number does not mean much.
And if your doctor does not give you a number, it is often not because they are hiding something, but because they know how poorly averages predict individual situations.
The figures in this article come from SEER data published by the American Cancer Society for patients diagnosed between 2014 and 2020, and from the surgical literature cited. They are informational and do not replace a discussion with your treating doctor, the only person who knows your actual situation.